Class Name(s):
Pronunciation:
Brand Name(s):
Other Name(s):
Fludarabine injection must be given under the supervision of a doctor who is experienced in giving chemotherapy medications for cancer.
Fludarabine injection can cause a severe decrease in the number of all types of blood cells in your blood. This may increase the risk you will develop a serious infection or bleeding. Tell your doctor if you have or have ever had a low number of any type of blood cells in your blood; any condition that affects your immune system; or if you have any type of infection now, or if you have or have ever had an infection that would not go away or an infection that comes and goes. If you experience any of the following symptoms, call your doctor immediately: unusual bleeding or bruising; black, tarry, or bloody stools; vomit that is bloody or that looks like coffee grounds; or fever, chills, cough, sore throat, difficult, painful, or frequent urination, or other signs of infection.
Fludarabine injection can also cause severe damage to the nervous system. If you experience any of the following symptoms, call your doctor immediately: seizures; agitation; confusion; coma (loss of consciousness for a period of time); vision changes; unusual weakness; or numbness, burning, pain, or tingling in the hands, arms, feet, or legs.
Fludarabine injection may cause serious or life-threatening conditions in which the body attacks and destroys its own blood cells. Tell your doctor if you have ever developed this type of condition after receiving fludarabine in the past. If you experience any of the following symptoms, call your doctor immediately: shortness of breath, fast or irregular heartbeat; headache; lightheadedness; pale skin; unusual tiredness or weakness, tiny red or purple dots on the skin, nosebleeds, heavy menstrual bleeding, or blood in the urine or stool.
Keep all appointments with your doctor and the laboratory. Your doctor will order certain tests to check your body's response to fludarabine injection.
Talk to your doctor about the risks of receiving fludarabine injection.
WHY is this medicine prescribed?
Fludarabine injection is used to treat certain types of chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells). Fludarabine injection is in a class of medications called purine analogs. It works by slowing or stopping the growth of cancer cells in your body.
HOW should this medicine be used?
Fludarabine injection comes as a solution (liquid) and a powder to be mixed with liquid and injected over 30 minutes intravenously (into a vein) by a doctor or nurse in a medical facility. Your doctor will tell you how often you will receive fludarabine injection. The schedule depends on the condition you have and on how your body responds to the medication.
Your doctor may need to delay your treatment or adjust your dose if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with fludarabine injection.
Are there OTHER USES for this medication?
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What SPECIAL PRECAUTIONS should I follow?
Before receiving fludarabine injection,
What SPECIAL DIETARY instructions should I follow?
Unless your doctor tells you otherwise, continue your normal diet.
What SIDE EFFECTS can this medicine cause?
Fludarabine injection may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
Some side effects can be serious. If you experience any of these symptoms or those listed in the IMPORTANT WARNING section, call your doctor immediately:
Fludarabine injection may increase the risk that you will develop skin cancer. Talk to your doctor about the risks of receiving this medication.
Fludarabine injection may cause other side effects. Call your doctor if you have any unusual problems while receiving this medication.
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
What OTHER INFORMATION should I know?
Keep a written list of all of the prescription and nonprescription (over-the-counter) medicines vitamins, minerals, and dietary supplements you are taking. Bring this list with you each time you visit a doctor or if you are admitted to the hospital. You should carry the list with you in case of emergencies.
¶ This branded product is no longer on the market. Generic alternatives may be available.
This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.
The American Society of Health-System Pharmacists, Inc. represents that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information is not a substitute for medical care.
AHFS® Patient Medication Information™ Copyright, 2025. The American Society of Health-System Pharmacists®, 4500 East-West Highway, Suite 900, Bethesda, Maryland. All Rights Reserved. Duplication for commercial use must be authorized by ASHP.
Selected Revisions: April 15, 2025.